# INVICTUS

Source: https://onco.cc/trials/invictus/  
OnCo record `invictus` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ripretinib kept fourth-line GIST under control six times longer than placebo and improved survival.

## Summary

INVICTUS, trial NCT03353753 sponsored by Deciphera and published in Lancet Oncology in 2020, showed that the switch-control kinase inhibitor ripretinib keeps fourth-line gastrointestinal stromal tumour under control roughly six times longer than placebo and improves survival. It randomised 129 patients after at least three kinase inhibitors and met its primary progression-free survival endpoint with a very large effect and a survival benefit, leading to approval in May 2020. OnCo links it to sarcomas and GIST, KIT as a target and ripretinib. Whether ripretinib can move earlier in the sequence, which INTRIGUE and the mutation-selected INSIGHT trial address, is the open question.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT03353753
- Phase: 3
- Setting: Advanced GIST after ≥3 kinase inhibitors: ripretinib vs placebo
- Sponsor: Deciphera
- Enrolled: 129
- Result: PFS HR 0.15; OS HR 0.36.
- Outcomes: Progression-free survival (median): Ripretinib 6.3 months vs Placebo 1 months, HR 0.15; Overall survival (median): Ripretinib 15.1 months vs Placebo 6.6 months, HR 0.36

## Sources

- ClinicalTrials.gov NCT03353753: https://clinicaltrials.gov/study/NCT03353753

## Connected records

- cancers: [Imatinib-resistant GIST](https://onco.cc/cancers/gist-imatinib-resistant/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [KIT](https://onco.cc/targets/kit/)
- drugs: [Ripretinib](https://onco.cc/drugs/ripretinib/)
- companies: [Deciphera Pharmaceuticals (Ono)](https://onco.cc/companies/deciphera/)
- key papers: [INVICTUS: ripretinib in advanced gastrointestinal stromal tumours after three or more prior kinase inhibitors](https://onco.cc/key-papers/paper-invictus-ripretinib-lancet-oncol-2020/)

---
JSON: https://onco.cc/api/v1/entities/invictus.json